Analyst Research

Report Title Price
Provider: Plunkett Research, Ltd.
$99.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc Receives Offer For Thrombosis Brands


Tuesday, 18 Jun 2013 07:00am EDT 

GlaxoSmithKline announced that it has received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited. A period of exclusivity has been agreed with Aspen and GSK will respond to the offer subject to consultation with employees and the relevant works councils. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine (excluding China, India and Pakistan) brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees. 

Company Quote

19.695
-0.134 -0.68%
21 Jul 2014